Primary Application
For what
Blood and Cardiovascular
Immune and Lymphatic
Integumentary
Mitochondrial and Energy Production
Source
Allopathy
For whom
People
All Trans Retinoic Acid (ATRA) is FDA approved in the treatment of promyelocytic leukemia. ATRA is a strong differentiating agent. As such, ATRA has potential as a therapy in a number of cancers, especially in the context of IC medicines. ATRA binds to retinoic acid receptors, and subsequently activates DNA transcription activity to move immature (e.g. malignant) cells toward normal maturation. Consider the use of ATRA in cases of cancer and precancerous lesions, including polyps, actinic keratosis, and others.
Similar ICs
301
40.3 k
10
603
174
107 k
163
53.7 k
119
34.9 k
10
448
372
49.9 k
455
132 k
440
75.1 k
217
19.2 k
Please select language
Select